DETAILED ACTION
Notice of Pre-AIA or AIA Status
The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA .
In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status.
Priority
Receipt is acknowledged of certified copies of papers required by 37 CFR 1.55.
Double Patenting
The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).
A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on nonstatutory double patenting provided the reference application or patent either is shown to be commonly owned with the examined application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. See MPEP § 717.02 for applications subject to examination under the first inventor to file provisions of the AIA as explained in MPEP § 2159. See MPEP § 2146 et seq. for applications not subject to examination under the first inventor to file provisions of the AIA . A terminal disclaimer must be signed in compliance with 37 CFR 1.321(b).
The filing of a terminal disclaimer by itself is not a complete reply to a nonstatutory double patenting (NSDP) rejection. A complete reply requires that the terminal disclaimer be accompanied by a reply requesting reconsideration of the prior Office action. Even where the NSDP rejection is provisional the reply must be complete. See MPEP § 804, subsection I.B.1. For a reply to a non-final Office action, see 37 CFR 1.111(a). For a reply to final Office action, see 37 CFR 1.113(c). A request for reconsideration while not provided for in 37 CFR 1.113(c) may be filed after final for consideration. See MPEP §§ 706.07(e) and 714.13.
The USPTO Internet website contains terminal disclaimer forms which may be used. Please visit www.uspto.gov/patent/patents-forms. The actual filing date of the application in which the form is filed determines what form (e.g., PTO/SB/25, PTO/SB/26, PTO/AIA /25, or PTO/AIA /26) should be used. A web-based eTerminal Disclaimer may be filled out completely online using web-screens. An eTerminal Disclaimer that meets all requirements is auto-processed and approved immediately upon submission. For more information about eTerminal Disclaimers, refer to www.uspto.gov/patents/apply/applying-online/eterminal-disclaimer.
Claim 1 is provisionally rejected on the ground of nonstatutory double patenting as being unpatentable over claims 12-13 of copending Application No. 18/575527 (reference application). Although the claims at issue are not identical, they are not patentably distinct from each other because the claims of the reference Application anticipate the claims of the current Application (i.e. they teach at least all the limitations of the current application). Note the difference of the syringe limitations between the claims are covered by the standard definition of a syringe.
This is a provisional nonstatutory double patenting rejection because the patentably indistinct claims have not in fact been patented.
Drawings
The Drawing amendments filed 27 May 2026 are accepted and entered. However, there are new objection issues detailed below.
The drawings are objected to because of the following:
Reference “315” is repeated in Fig 14A, which may lead to confusion as to whether there is a mistake in the Drawings, or whether there must be two of 315 in the figure.
The quality of lines Fig 14 in the Amendment is lower than the original drawing. It is recommended that the lines be made sufficiently, bold, dark, and clear in subsequently filed amended drawings.
Corrected drawing sheets in compliance with 37 CFR 1.121(d) are required in reply to the Office action to avoid abandonment of the application. Any amended replacement drawing sheet should include all of the figures appearing on the immediate prior version of the sheet, even if only one figure is being amended. The figure or figure number of an amended drawing should not be labeled as “amended.” If a drawing figure is to be canceled, the appropriate figure must be removed from the replacement sheet, and where necessary, the remaining figures must be renumbered and appropriate changes made to the brief description of the several views of the drawings for consistency. Additional replacement sheets may be necessary to show the renumbering of the remaining figures. Each drawing sheet submitted after the filing date of an application must be labeled in the top margin as either “Replacement Sheet” or “New Sheet” pursuant to 37 CFR 1.121(d). If the changes are not accepted by the examiner, the applicant will be notified and informed of any required corrective action in the next Office action. The objection to the drawings will not be held in abeyance.
Specification
Amendments to the Specification filed 27 May 2026 are accepted and entered.
Claim Objections
Claims are objected to because of the following informalities:
Cl.1: “removable received” is believed to be in error for --removably received--
Cl.17: “and wherein the clutch is configured for moving” is believed to be in error for --and wherein the clutch is configured for: moving--
Appropriate correction is required.
Claim Rejections - 35 USC § 102
The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:
A person shall be entitled to a patent unless –
(a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale or otherwise available to the public before the effective filing date of the claimed invention.
(a)(2) the claimed invention was described in a patent issued under section 151, or in an application for patent published or deemed published under section 122(b), in which the patent or application, as the case may be, names another inventor and was effectively filed before the effective filing date of the claimed invention.
Claim(s) 1-8, 15-17, and 20-23 is/are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Bechmann 9186459.
Regarding Claim 1, Bechmann teaches a system for administration of medicament (904 held in 20, 900), the system comprising a cassette (incl. 900, 20, 902, 908, 800, 600, 500) and an auto injector (incl. 1800, 1400, 1700, 1500, 1600, 1100) adapted for receiving the cassette (all assembled together per Fig 1);
wherein the cassette comprises:
a syringe (900, 20) comprising:
a syringe medicament compartment (900);
an outlet (needle 902) at the proximal end (at 902) of the syringe compartment (Fig 1); and
a stopper (908) positioned inside the syringe compartment (Fig 6A), wherein the stopper is movable from a distal end (toward 1510) of the syringe compartment towards the proximal end of the syringe compartment for emptying the medicament in the syringe compartment through the outlet (Figs 6A-B);
a syringe holder (800, fixed with 1100) for receiving the syringe (Figs 1, 9);
a skin sensor (600) longitudinally movable relative to the syringe holder (800 fixed with 1100 comprising 1112; Figs 9-10) between two or more longitudinal positions selected from:
a distal position (Fig 10C);
a final locked position (Figs 10D; “the two clips of the skin sensor are resting on a shelf on the syringe lock, locking them in position to protect the needle” col.26 ll.43-45);
an initial locked position (10A) between the final locked position and the distal position (relative position of 600 and 800 in Fig 10A is axially between the relative positions in Fig 10C and Fig 10D; also in Fig 10A, 1112 locked against proximal axial translation); and
an intermediate position (at least Fig 10B) between the initial locked position and the final locked position (relative position of 600 and 800 being axially between the relative positions of Figs 10A and 10D);
an index ring (500) rotatable relative to the skin sensor (Fig 10) between two or more rotational positions selected from:
a first rotational position (Figs 10A and 10E);
a delivery rotational position (Fig 10C-D) in which the skin sensor is moveable between the distal position and the final locked position;
a cap-release (the term cap-release is considered mostly nominal, there being no cap or other cap-release limitations recited in the claim; nevertheless, it can be seen that in Fig 10B any cap on the device has been released, thus satisfying the term “cap-release”) rotational position (Fig 10B) positioned between the first rotational position and the delivery rotational position (compare Figs 10A-E);
wherein the auto injector is extending from a proximal end (at 1510) to a distal end (at 1800) along a longitudinal axis (Figs 1, 6), wherein the cassette is disposable (col.3 ll.32-41; the auto-injector is meant to be disposed of after use, thus every part of the injector is also disposable, including the cassette; furthermore the exploded view of Fig 1 along with the explanation in col.15 l. 65 - col.16 l.3 demonstrates how the cassette portions may be removed and thus capable of disposal or replacement if necessary) and removably received in the auto injector along the longitudinal axis in a longitudinal direction (cassette portions must be removable from auto-injector portions in order to replace the syringe; col.15 l.65 – col.16 l.3; furthermore the exploded view of Fig 1 demonstrates how the cassette portions may be removed and thus capable of disposal or replacement if necessary);
wherein the auto injector comprises an injector housing (incl. 1800 and parts of 1400; may also include at least part of 400) and a multiple of internal injector parts (incl. 1400, 1700, 1500, 1600, 1100 incl. 11112) positioned inside the injector housing (Figs 1 and 6A show all the components at least partially within 1800), wherein the internal injector parts includes at least:
a plunger rod (1500) configured for proximal movement of the stopper inside the cassette (Fig 6);
a drive module (incl. 1600) adapted for moving the plunger rod proximately (Figs 1, 6); and
one or more release members (semi-annular members of 1100 at 1101 from which 1112 extend radially) configured for rotating the index ring (Fig 10) between the two or more rotational positions when the one or more release members moves proximally (Fig 10).
Regarding Claim 2, Bechmann teaches all the limitations of the claimed invention as discussed above. Bechmann further teaches wherein the internal injector parts of the auto injector includes a skin sensor spring system (incl. 700) adapted for pushing the skin sensor proximal (col.22 ll.3-7), wherein when the one or more release members travels proximally into the cassette and comes in contact with the index ring (at 506; Fig 10A), the index ring rotates from the first rotational position (Fig 10A) towards the cap-release rotational position (Fig 10B), whereby the skin sensor spring system pushes the skin sensor proximally (spring 700 still compressed in Fig 10B and pushing proximally on skin sensor 600).
Regarding Claim 3, Bechmann teaches all the limitations of the claimed invention as discussed above. Bechmann further teaches when the skin sensor is in the distal longitudinal position (Fig 10C), the syringe outlet (902) is exposed, and wherein the skin sensor covers the syringe outlet when the skin sensor is in either of:
the initial locked position (Fig 10A);
the intermediate position (Fig 10B); and
the final locked position (Fig 10D).
Regarding Claim 4, Bechmann teaches all the limitations of the claimed invention as discussed above. Bechmann further teaches the index ring is configured for moving from the cap-release rotational position to the delivery rotational position preparing the system for medicament delivery when the skin sensor is in the distal longitudinal position (Fig 10C).
Regarding Claim 5, Bechmann teaches all the limitations of the claimed invention as discussed above. Bechmann further teaches the index ring comprises a track (incl. 506, 510) extending in a sloping direction (Fig 10), wherein the one or more release members is configured for traveling inside the track (Fig 10), and wherein the index ring is rotated when the one or more release member travel proximally inside the track (Fig 10).
Regarding Claim 6, Bechmann teaches all the limitations of the claimed invention as discussed above. Bechmann further teaches each of the one or more release members comprises a track-guide protrusion (1112), and wherein the track-guide protrusion is configured for traveling inside the track (Fig 10).
Regarding Claim 7, Bechmann teaches all the limitations of the claimed invention as discussed above. Bechmann further teaches the injector housing comprises: a cassette covering section (proximal portion including 402 in Fig 2C) extending to cover at least a part of the cassette (Fig 1) when received inside the injector (Figs 1-2); and a distal housing section (distal portion toward and/or including 1800) extending to cover the internal injector parts inside the injector housing before the cassette is secured inside the injector (Fig 1).
Regarding Claim 8, Bechmann teaches all the limitations of the claimed invention as discussed above. Bechmann further teaches the injector comprises one or more cassette interacting parts (apertures in 1800 that mate with tabs on 1300) configured for engaging in a snap-fit connection with corresponding one or more cassette securing tabs (on 1300) on the cassette when the cassette is inserted into the injector, and wherein proximal movement of the one or more release members prevents a disengagement of the snap-fit connection thereby securing the cassette inside the auto injector (Figs 6A-E).
Regarding Claim 15, Bechmann teaches all the limitations of the claimed invention as discussed above. Bechmann further teaches the internal injector parts further includes a clutch (incl. 1420, 1422, 1108, 1110, 1508) configured for being movable between:
a first clutch position where the plunger rod and the one or more release members are longitudinally coupled for proximal movement together (Figs 7A-D); and
a second clutch position where the plunger rod is decoupled from the one or more release members allowing the plunger rod to move longitudinally while the one or more release members are longitudinally stationary (Figs 7C-F).
Regarding Claim 16, Bechmann teaches all the limitations of the claimed invention as discussed above. Bechmann further teaches the one or more release members are coupled to the injector housing in the second clutch position (release members are always contained in the injector housing 400, 1800 and therefor, coupled – albeit perhaps indirectly – thereto).
Regarding Claim 17, Bechmann teaches all the limitations of the claimed invention as discussed above. Bechmann further teaches the clutch is in the first clutch position prior to use (Fig 7A-B; col.23 ll.36-39) and wherein the clutch is configured for: moving from the first clutch position to the second clutch position when the index ring is rotated to the delivery rotational position by proximal movement of the one or more release members (7C-F at least one of which corresponding to at least Fig 10C).
Regarding Claim 20, Bechmann teaches all the limitations of the claimed invention as discussed above. Bechmann further teaches the clutch is a tubular clutch (incl. tubular parts of 1110 and 1400, including 1108,1110 and 1420,1422, respectively) having one or more clutch tabs (1108, 1110; or 1508) with a first rotation surface (cylinder of 1100 at the axial location of 1110; or Fig 7N below) and a second rotation surface (cylinder of 1100 at the axial location of 1108; or Fig 7N below), and
PNG
media_image1.png
540
911
media_image1.png
Greyscale
wherein the internal injector parts comprises a proximal chassis part (axially extended, smaller diameter portion of 1400 including 1420 and 1422; or axially extended, smaller diameter portion of 1100) having a clutch coupling part (cylindrical part including 1420 and 1422; or portion of 1100 depicted in Fig 7N) with one or more first coupling surfaces (cylinder of 1400 at 1422; or 1109) and one or more second coupling surfaces (cylinder of 1400 at 1420; or Fig 7N above), wherein:
when the second rotation surface on the clutch is abutting the one or more second coupling surfaces (interpreted under 112b above) on the clutch coupling part, the clutch is in the second clutch position (when the cylindrical parts of 1108 and 1420 abut/coincide, the clutch is in the second position; when 1508 passes 1109, the second rotation surface abuts the second coupling surface and the rod 1500 slides relative to 1100 per Figs 7A-F); and
when the second rotation surface on the clutch is not in contact with the one or more second coupling surfaces (interpreted under 112b above) on the clutch coupling part, the clutch is in the first clutch position (Figs 7A-7B and 7M; when the cylindrical parts of 1108 and 1420 are not abutting/coinciding; in the first clutch position, the second rotation surface of 1508 does not abut the second coupling surface of 1100).
Regarding Claim 21, Bechmann teaches all the limitations of the claimed invention as discussed above. Bechmann further teaches the plunger rod is configured for moving in the longitudinal direction relative to the clutch (when the clutch is in the second clutch position), wherein the clutch is configured for:
moving proximally with the one or more release members before the second rotation surface comes into contact with the one or more second coupling surfaces (1508 is engaged with 1109,1108 to move together with 1100 until 1108 aligns with 1420 and 1508 slips past 1109 for the second rotation surface to contact the second coupling surface);
axial rotation when the second rotation surface comes into contact with the one or more second coupling surfaces, thereby moving from the first clutch position to the second clutch position (1108 and 1109 rotate radially outward when they align with 1420 and 1508/1509 slips past 1108/1109 for the second rotation surface to contact the second coupling surface; thus switching from the first to the second clutch position).
Regarding Claim 22, Bechmann teaches all the limitations of the claimed invention as discussed above. Bechmann further teaches the clutch coupling part comprises a clutch stopping surface (cylinder of 1400 axially between 1420 and 1422) abutting the clutch when the clutch is in the second clutch position (cylinder of 1400 axially between 1420, 1422 abuts the clutch component 1108 when the clutch is in the second clutch position) thereby preventing the clutch and the one or more release members from moving longitudinally with the plunger rod (7C-F).
Regarding Claim 23, Bechmann teaches all the limitations of the claimed invention as discussed above. Bechmann further teaches the plunger rod comprises a stopping clutch tab (1508), wherein a distal surface (1509 ;distal relative to the following claimed proximal surface) of the stopping clutch tab is abutting a proximal surface (1109) of the one or more release members when the clutch is in the first clutch position (Fig 7M),
wherein the stopping clutch tab is configured for moving the clutch from the second clutch position to the first clutch position upon distal movement of the plunger rod bringing the distal surface of the stopping clutch tab in contact with the proximal surface of the one or more release members (based on the structural features and operation of the clutch from Figs 7A-F, physically moving the plunger distally would result in a change from the second clutch position to the first clutch position).
Potentially Allowable Subject Matter
Claims 9-11 and 13-14 are objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims.
Response to Arguments
Applicant's arguments filed 27 May 2026 have been fully considered but they are not persuasive.
Applicant argues that adding the term “disposable” overcomes the prior art because the prior art auto-injector of Bechmann reuses its components for a second injection.
However, this re-use does not change the fact that the entire injector is a disposable auto-injector. Thus, after usage the auto-injector, and any subcomponent thereof, is disposable. Furthermore, the exploded view of Fig 1 along with the explanation in col.15 l. 65 - col.16 l.3 demonstrates how the cassette portions may be removed and thus capable of disposal or replacement if necessary.
Conclusion
Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).
A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.
Correspondence
Any inquiry concerning this communication or earlier communications from the examiner should be directed to STEPHANIE SEBASCO CHENG whose telephone number is (469)295-9153. The examiner can normally be reached 0600-0900 AM ET M-F and 1-2PM T/R.
Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice.
If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Phutthiwat Wongwian can be reached at 571-270-5426. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.
Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.
/STEPHANIE SEBASCO CHENG/Primary Examiner, Art Unit 3741